Volume 10, Number 3—March 2004
Dispatch
Endemic Carbapenem-resistant Pseudomonas aeruginosa with Acquired Metallo-β-lactamase Determinants in European Hospital
Table 1
No. of isolates | RAPD–AFLP genotypesb | blaVIM allele | Hospital wards (patients) | Long-term care facilities (patients) | Outpatients | |
---|---|---|---|---|---|---|
blaVIM-positive |
||||||
53 |
A |
blaVIM-1-like |
15 (43) |
3 (4) |
6 |
|
8 |
B |
blaVIM-2-like |
4c (8) |
- |
- |
|
1 |
C |
blaVIM-2-like |
1d (1) |
- |
- |
|
1 |
D |
blaVIM-2-like |
- |
1 (1) |
- |
|
1 |
E |
blaVIM-1-like |
- |
- |
1 |
|
blaVIM-negative |
||||||
5 |
A |
None |
2 (3) |
- |
2 |
|
1 |
B |
None |
1 (1) |
- |
- |
|
19 | F-G-H-I-J-Ke | None | 8 (16) | 1 (1) | 2 |
a MBL, metallo-β-lactamase.
bRAPD–AFLP, Random Amplification of Polymorphic DNA–Amplified Fragment Length Polymorphism. Results obtained with the two genotyping techniques were always consistent with each other.
cIn these wards isolates of cluster A were also detected.
dIn this ward isolates of clusters A and B were also detected.
eGenotypes F to K included a number of isolates ranging from 1 to 7.
Page created: February 08, 2011
Page updated: February 08, 2011
Page reviewed: February 08, 2011
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.